[{"address1": "Paasheuvelweg 25", "city": "Amsterdam", "zip": "1105 BP", "country": "Netherlands", "phone": "31 20 240 6000", "website": "https://www.uniqure.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.", "fullTimeEmployees": 480, "companyOfficers": [{"maxAge": 1, "name": "Mr. Matthew Craig Kapusta", "age": 51, "title": "CEO & Executive Director", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 1017357, "exercisedValue": 0, "unexercisedValue": 96250}, {"maxAge": 1, "name": "Mr. Christian  Klemt", "age": 50, "title": "CFO, Principal Financial Officer & GM of Amsterdam Site", "yearBorn": 1973, "fiscalYear": 2023, "totalPay": 575462, "exercisedValue": 0, "unexercisedValue": 21000}, {"maxAge": 1, "name": "Mr. Richard  Porter Ph.D.", "age": 55, "title": "Chief Business & Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 732169, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jeannette  Potts J.D., Ph.D.", "age": 61, "title": "Chief Legal & Compliance Officer and Corporate Secretary", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 635561, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Hugo  Katus", "title": "Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Amin  Abujoub Ph.D.", "title": "Chief Technical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tamara  Tugal Ph.D., MBA", "title": "Business Development Director", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin  Boyer", "title": "Chief People & Culture Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maria E. Cantor", "age": 55, "title": "Chief Corporate Affairs Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 491122, "exercisedValue": 0, "unexercisedValue": 1087760}, {"maxAge": 1, "name": "Dr. Walid  Abi-Saab M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 3, "compensationRisk": 6, "shareHolderRightsRisk": 1, "overallRisk": 3, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 6.28, "open": 6.28, "dayLow": 6.182, "dayHigh": 6.46, "regularMarketPreviousClose": 6.28, "regularMarketOpen": 6.28, "regularMarketDayLow": 6.182, "regularMarketDayHigh": 6.46, "beta": 0.944, "forwardPE": -2.3093526, "volume": 659773, "regularMarketVolume": 659773, "averageVolume": 717115, "averageVolume10days": 904270, "averageDailyVolume10Day": 904270, "marketCap": 312638592, "fiftyTwoWeekLow": 3.73, "fiftyTwoWeekHigh": 11.35, "priceToSalesTrailing12Months": 11.28374, "fiftyDayAverage": 5.7941, "twoHundredDayAverage": 5.687875, "currency": "USD", "enterpriseValue": 322649728, "floatShares": 37985117, "sharesOutstanding": 48697600, "sharesShort": 5257182, "sharesShortPriorMonth": 4508201, "sharesShortPreviousMonthDate": 1724976000, "dateShortInterest": 1727654400, "sharesPercentSharesOut": 0.108, "heldPercentInsiders": 0.0433, "heldPercentInstitutions": 0.73193, "shortRatio": 11.03, "shortPercentOfFloat": 0.1091, "bookValue": 1.994, "priceToBook": 3.219659, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -284694016, "trailingEps": -5.92, "forwardEps": -2.78, "enterpriseToRevenue": 11.645, "enterpriseToEbitda": -1.486, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "QURE", "underlyingSymbol": "QURE", "shortName": "uniQure N.V.", "longName": "uniQure N.V.", "firstTradeDateEpochUtc": 1391610600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e051aa7b-edc2-3bc7-a8c8-c2e424dc5a80", "gmtOffSetMilliseconds": -14400000, "currentPrice": 6.42, "targetHighPrice": 28.0, "targetLowPrice": 7.0, "targetMeanPrice": 19.18, "targetMedianPrice": 18.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 11, "totalCash": 524430016, "totalCashPerShare": 10.769, "ebitda": -217116992, "totalDebt": 534440992, "quickRatio": 6.615, "currentRatio": 7.357, "totalRevenue": 27707000, "debtToEquity": 550.363, "revenuePerShare": 0.575, "returnOnAssets": -0.17119, "returnOnEquity": -1.2641101, "freeCashflow": -68173248, "operatingCashflow": -103916000, "revenueGrowth": 3.594, "operatingMargins": -4.25993, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-21"}]